Novel serine threonine kinase member, h2520-59
AssigneeAmgen Inc.
InventorsJohn Boylan, Alex Bowers
Life of this patent
Estimating the term…
Abstract
The present invention relates to a serine threonine kinase. The invention also relates to nucleic acids encoding the kinase, vectors, host cells, antibodies and recombinant methods for producing the h2520-59 polypeptide. In addition, the invention discloses therapeutic, diagnostic and research utilities for h2520-59 and related products.
Claims36
1-24. (canceled)
An antibody produced by immunizing an animal with a peptide comprising an amino acid sequence of SEQ ID NO:
- 2.
An antibody or fragment thereof that specifically binds the polypeptide comprising the amino acid sequence set forth in SEQ ID NO:
- 2.
A hybridoma that produces a monoclonal antibody that binds to a peptide comprising an amino acid sequence of SEQ ID NO:
- 2.
A selective binding agent or fragment thereof that specifically binds at least one polypeptide wherein said polypeptide comprises the amino acid sequence set forth in SEQ ID NO:
- 2.
(canceled)
A selective binding agent or fragment thereof comprising at least one complementarity determining region with specificity for a polypeptide having the amino acid sequence of SEQ ID NO:
- 2.
A selective binding agent produced by immunizing an animal with a polypeptide comprising the amino acid sequence of SEQ ID NO:
- 2.
A hybridoma that produces a selective binding agent capable of binding a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:
- 2.
47-78. (canceled)
A selective binding agent that specifically binds a first polypeptide with an amino acid sequence comprising the amino acid sequence set forth in SEQ ID NO:
- 2, and antagonizes the binding of the first polypeptide to an activating transcription factor-4 (ATF-4) polypeptide.
Dependencies are inferred from the claim text.